Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide

References

• SalibaWEl-HaddadBSecondary hyperparathyroidism: pathophysiology and treatmentJ Am Board Fam Med20092257458119734404
   PubMed Web of Science ®Google Scholar
• BrownAJSlatopolskyEDrug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney diseaseNat Clin Pract Endocrinol Metab2007313414417237840
   PubMedGoogle Scholar
• JoyMSKaragiannisPCPeyerlFWOutcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatmentJ Manag Care Pharm20071339741117605511
   PubMed Web of Science ®Google Scholar
• McCannLMBetoJRoles of calcium-sensing receptor and vitamin D receptor in the pathophysiology of secondary hyperparathyroidismJ Ren Nutr20102014115020303786
   PubMed Web of Science ®Google Scholar
• MoeSMDruekeTBManagement of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus productAm J Nephrol20032336937914551461
   PubMed Web of Science ®Google Scholar
• CozzolinoMUrena-TorresPVervloetMGIs chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Nephrol Dial Transplant201429101815182024516228
   PubMed Web of Science ®Google Scholar
• RiccardiDBrownEMPhysiology and pathophysiology of the calcium-sensing receptor in the kidneyAm J Physiol Renal Physiol2010298F485F49919923405
   PubMed Web of Science ®Google Scholar
• GallieniMCozzolinoMFallabrinoGVitamin D: physiology and pathophysiologyInt J Artif Organs200932879419363780
   PubMed Web of Science ®Google Scholar
• EvenepoelPRodriguezMKettelerMLaboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?Semin Nephrol20143415116324780470
   PubMed Web of Science ®Google Scholar
• WetmoreJBQuarlesLDTreatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogsInt J Nephrol Renovasc Dis2008151721694914
   PubMedGoogle Scholar
• CunninghamJLocatelliFRodriguezMSecondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic optionsClin J Am Soc Nephrol2011691392121454719
   PubMed Web of Science ®Google Scholar
• GoodmanWGQuarlesLDDevelopment and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular geneticsKidney Int20087427628817568787
   PubMed Web of Science ®Google Scholar
• CozzolinoMCiceriPVolpiEMPathophysiology of calcium and phosphate metabolism impairment in chronic kidney diseaseBlood Purif20092733834419295196
   PubMed Web of Science ®Google Scholar
• NakajimaKUminoKAzumaYStimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged periodJ Bone Miner Metab20092722423319194773
   PubMed Web of Science ®Google Scholar
• DruekeTBMassyZACirculating Klotho levels: clinical relevance and relationship with tissue Klotho expressionKidney Int201383131523271484
   PubMed Web of Science ®Google Scholar
• MoeSMThadhaniRWhat have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?Curr Opin Nephrol Hypertens20132265165524100218
   PubMed Web of Science ®Google Scholar
• RossiMCampbellKLJohnsonDWIndoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxinsOA Nephrology2013113
   Google Scholar
• YoungEWAlbertJMSatayathumSPredictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns StudyKidney Int2005671179118715698460
   PubMed Web of Science ®Google Scholar
• TentoriFBlayneyMJAlbertJMMortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)Am J Kidney Dis20085251953018514987
   PubMed Web of Science ®Google Scholar
• FukagawaMKidoRKomabaHAbnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confoundingAm J Kidney Dis20146397998724119541
   PubMed Web of Science ®Google Scholar
• StubbsJRWetmoreJBDoes it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Semin Dial20112429830621682772
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)Kidney Int Suppl2009113S1S130
   Google Scholar
• GalassiACupistiASantoroACozzolinoMPhosphate balance in ESRD: diet, dialysis and binders against the low evident masked poolJ Nephrol20152841542925245472
   PubMed Web of Science ®Google Scholar
• SekerciogluNAngeliki VeronikiAThabaneLEffects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: a systematic review and NMAPLoS One2017123e017102828248961
   PubMed Web of Science ®Google Scholar
• CozzolinoMTomlinsonJWalshLBellasiAEmerging drugs for secondary hyperparathyroidismExpert Opin Emerg Drugs201520219720825702624
   PubMed Web of Science ®Google Scholar
• CozzolinoMMazzaferroSBrandenburgVThe treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?Nephrol Dial Transplant20112640240721079194
   PubMed Web of Science ®Google Scholar
• AndersonJJKruszkaBDelaneyJACalcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the Multi-Ethnic Study of Atherosclerosis (MESA)J Am Heart Assoc20165e00381527729333
   PubMed Web of Science ®Google Scholar
• PalmerSCGardnerSTonelliMPhosphate-binding agents in adults with CKD: a network meta-analysis of randomized trialsAm J Kidney Dis201668569170227461851
   PubMed Web of Science ®Google Scholar
• di FilippoSCarfagnaFla MiliaVAssessment of intradialysis calcium mass balance by single pool variable-volume calcium kinetic modelHemodial Int Epub201725
   PubMed Web of Science ®Google Scholar
• BlockGAMartinKJde FranciscoALCinacalcet for secondary hyperparathyroidism in patients receiving hemodialysisN Engl J Med20043501516152515071126
   PubMed Web of Science ®Google Scholar
• BellasiACozzolinoMCinacalcet: the chemical parathyroidectomy?Clin Kidney J20136325325626064483
   PubMedGoogle Scholar
• FishbaneSShapiroWBCorryDBCinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study resultsClin J Am Soc Nephrol200831718172518945995
   PubMed Web of Science ®Google Scholar
• MessaPMacarioFYaqoobMThe OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismClin J Am Soc Nephrol20083364518178780
   PubMed Web of Science ®Google Scholar
• Evolve Trial InvestigatorsEffect of cinacalcet on cardiovascular disease in patients undergoing dialysisN Engl J Med20123672482249423121374
   PubMed Web of Science ®Google Scholar
• ParfreyPSChertowGMBlockGAThe clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialJ Clin Endocrinol Metab2013984834484424108314
   PubMed Web of Science ®Google Scholar
• BellasiACozzolinoMAdragaoTPhosphate binders in moderate chronic kidney disease: where do we stand?J Nephrol201326993100023543481
   PubMed Web of Science ®Google Scholar
• RaggiPChertowGMTorresPUThe ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysisNephrol Dial Transplant2011261327133921148030
   PubMed Web of Science ®Google Scholar
• BellasiAReinerMPétavyFGoodmanWFloegeJRaggiPPresence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE studyJ Heart Valve Dis201322339139924151766
   PubMed Web of Science ®Google Scholar
• Ureña-TorresPAFloegeJHawleyCMProtocol adherence and the progression of cardiovascular calcification in the ADVANCE studyNephrol Dial Transplant201328114615223028103
   PubMed Web of Science ®Google Scholar
• BellasiACozzolinoMRussoDMolonyDDi IorioBCinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT studyClin Nephrol201686911312427443567
   PubMed Web of Science ®Google Scholar
• GoldsmithDJCovicAFouqueDEndorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statementNephrol Dial Transplant201025123823383120829401
   PubMed Web of Science ®Google Scholar
• MorroneLFBolascoPCameriniCVitamin D in patients with chronic kidney disease: a position statement of the Working Group “Trace Elements and Mineral Metabolism” of the Italian Society of NephrologyJ Nephrol20162930532827062486
   PubMed Web of Science ®Google Scholar
• NICEChronic kidney disease in adults: assessment and management clinical guideline Pub Available from: https://nice.org.uk/guidance/cg182Accessed July 23, 2014
   Google Scholar
• KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney diseaseKidney Int Suppl2013311150
   Web of Science ®Google Scholar
• KandulaPDobreMScholdJDSchreiberMJJrMehrotraRNavaneethanSDVitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trialsClin J Am Soc Nephrol20116506220876671
   PubMed Web of Science ®Google Scholar
• NigwekarSUBhanIThadhaniRErgocalciferol and cholecalciferol in CKDAm J Kidney Dis201260113915622560832
   PubMed Web of Science ®Google Scholar
• TripkovicLLambertHHartKComparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysisAm J Clin Nutr20129561357136422552031
   PubMed Web of Science ®Google Scholar
• WetmoreJBKimberCMahnkenJDStubbsJRCholecalciferolVErgocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trialBr J Nutr2016116122074208128065190
   PubMed Web of Science ®Google Scholar
• SpragueSMCrawfordPWMelnickJZUse of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney diseaseAm J Nephrol201644431632527676085
   PubMed Web of Science ®Google Scholar
• PetkovichMMelnickJWhiteJTabashSStrugnellSBishopCWModified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulationJ Steroid Biochem Mol Biol201514828328925446887
   PubMed Web of Science ®Google Scholar
• HamdyNAKanisJABenetonMNEffect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failureBMJ199531069763583637677827
   PubMed Web of Science ®Google Scholar
• BrownAJVitamin D analogs for secondary hyperparathyroidism: what does the future hold?J Steroid Biochem Mol Biol20071033–557858317368185
   PubMed Web of Science ®Google Scholar
• MartinKJGonzálezEAGellensMHammLLAbboudHLindbergJ19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysisJ Am Soc Nephrol199898142714329697664
   PubMed Web of Science ®Google Scholar
• FrazaoJMChesneyRWCoburnJWIntermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study GroupNephrol Dial Transplant199813Suppl 368729568825
   PubMed Web of Science ®Google Scholar
• CoyneDWGoldbergSFaberMGhosseinCSpragueSMA randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3–4 CKDClin J Am Soc Nephrol2014991620162624970869
   PubMed Web of Science ®Google Scholar
• MessaPCozzolinoMBrancaccioDFARO Study GroupEffect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational studyBMC Nephrol2015161125886515
   PubMed Web of Science ®Google Scholar
• KovesdyCPKalantar-ZadehKVitamin D receptor activation and survival in chronic kidney diseaseKidney Int200873121355136318288097
   PubMed Web of Science ®Google Scholar
• TentoriFAlbertJMYoungEWThe survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns StudyNephrol Dial Transplant200924396397219028748
   PubMed Web of Science ®Google Scholar
• TentoriFHuntWCStidleyCAMedical Directors of Dialysis Clinic IncMortality risk among hemodialysis patients receiving different vitamin D analogsKidney Int200670101858186517021609
   PubMed Web of Science ®Google Scholar
• MazzaferroSGoldsmithDLarssonTEMassyZACozzolinoMVitamin D metabolites and/or analogs: which D for which patient?Curr Vasc Pharmacol201412233934923713876
   PubMed Web of Science ®Google Scholar
• KimMJFrankelAHDonaldsonMOral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibitionKidney Int201180885186021832985
   PubMed Web of Science ®Google Scholar
• de BorstMHHajhosseinyRTamezHWengerJThadhaniRGoldsmithDJActive vitamin D treatment for reduction of residual proteinuria: a systematic reviewJ Am Soc Nephrol201324111863187123929770
   PubMed Web of Science ®Google Scholar
• ThadhaniRAppelbaumEPritchettYVitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trialJAMA2012307767468422337679
   PubMed Web of Science ®Google Scholar
• BrancaccioDCozzolinoMGallieniMHyperparathyroidism and anemia in uremic subjects: a combined therapeutic approachJ Am Soc Nephrol200415Suppl 1S21S2414684666
   PubMed Web of Science ®Google Scholar
• RiccioESabbatiniMBruzzeseDEffect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trialPLoS One2015103e011817425781618
   PubMed Web of Science ®Google Scholar
• GalassiABellasiAAuricchioSPapagniSCozzolinoMWhich vitamin D in CKD-MBD? The time of burning questionsBiomed Res Int2013201386401223991423
   PubMed Web of Science ®Google Scholar
• NarayanRPerkinsRMBerbanoEPParathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysisAm J Kidney Dis20074980181317533023
   PubMed Web of Science ®Google Scholar
• ConzoGPernaAFSavicaVImpact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics eraBMC Surg201313Suppl 2S424268127
   PubMed Web of Science ®Google Scholar
• Di IorioBMolonyDBellCINDEPENDENT Study InvestigatorsSevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trialAm J Kidney Dis201362477177823684755
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]Secondary Hyperparathyroidism Available from: https://clinicaltrials.govAccessed November 30, 2016
   Google Scholar
• BoverJUreña-TorresPLloretMJIntegral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcificationExpert Opin Pharmacother201617101363137327156578
   PubMed Web of Science ®Google Scholar
• BlairHAEtelcalcetide: first global approvalDrugs201676181787179227900648
   PubMed Web of Science ®Google Scholar
• MartinKJBellGPickthornKVelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsNephrol Dial Transplant20142938539224235081
   PubMed Web of Science ®Google Scholar
• SubramanianRZhuXKerrSJNonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium sensing receptor AMG 416 (Etelcalcetide)Drug Metab Dispos20164481319133126895981
   PubMed Web of Science ®Google Scholar
• SubramanianRZhuXHockMBPharmacokinetics, biotransformation, and excretion of [14C]Etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysisClin Pharmacokinetics2017562179192
   PubMed Web of Science ®Google Scholar
• MartinKJBlockGAChengSComparison of the Efficacy and Safety of Intravenous (IV) Etelcalcetide (AMG 416) and Oral Cinacalcet (CIN) in Patients on Hemodialysis (HD) with Secondary Hyperparathyroidism (sHPT)Abstract Poster presented at: Kidney WeekNovember 7; 2015San Diego, CA
   Google Scholar
• ChenPOlsson GisleskogPPerez-RuixoJJPopulation pharmacokinetics and pharmacodynamics of the calcimimetic Etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receivingCPT Pharmacometrics Syst Pharmacol2016548449427639083
   PubMedGoogle Scholar
• EdsonKZWuBMIyerAGoodmanWSkilesGLSubramanianRDetermination of Etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosingKidney Int Rep201612433
   PubMedGoogle Scholar
• BlockGABushinskyDAChengSEffect of Etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism a randomized clinical trialJAMA2017317215616428097356
   PubMed Web of Science ®Google Scholar
• FukagawaMYokoyamaKShigematsuTONO-5163 Study Group Efficacy and Safety of a Novel Intravenous CalcimimeticONO-5163 (ETELCALCETIDE) in Japanese hemodialysis patients with secondary hyperparathyroidism: results of a placebo controlled phase III studyNephrol Dial Transplant201631Suppl 1i454i471
   Google Scholar
• CunninghamJA long acting intravenous calcimimetic (AMG416) for secondary hyperparathyroidism (SHPT) in haemodialysed patientsPoster presented at: 52 nd ERA-EDTA Congress2015London, UK
   Google Scholar
• StollenwerkBBriggsADehmelBModelling Etelcalcetide effectiveness on health outcomes: relating biochemical outcomes to mortality, cardiovascular events, fractures and parathyroidectomyAbstract Poster presented at: 16th Biennial European Conference SMDMJune 12–24; 2016London, UK
   Google Scholar
• BellGHuangSOaksTMartinKJBlockGAA randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patientsCurr Med Res Opin201531594395225786369
   PubMed Web of Science ®Google Scholar
• YokoyamaKFukagawaMShigematsuTONO-5163 Study Group A novel Intravenous CalcimimeticsONO-5163 (ETELCALCETIDE): a multicenter single and multiple dose study in Japanese hemodialysis patients with secondary hyperparathyroidismNephrol Dial Transplant201631Suppl 1i454i471
   Google Scholar
• BlockGABushinskyDACunninghamJEffect of Etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism two randomized clinical trialsJAMA2017317214615528097355
   PubMed Web of Science ®Google Scholar
• BushinskyDABlockGAMartinKJTreatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptorAm J Nephrol201542537938826684933
   PubMed Web of Science ®Google Scholar
• BushinskyDABlockGAChengSOne year efficacy and safety of intravenous (IV) ETELCALCETIDE (AMG 416) in patients on hemodialysis (HD) with secondary hyperparathyroidism (SHPT)Abstract Poster presented at: 53rd ERA-EDTA CongressMay 21–24; 2016Vienna, Austria
   Google Scholar
• European Medicines Agency [homepage on the Internet]Parsabiv: summary of product characteristics Available from: http://www.ema.europa.euAccessed November 30, 2016
   Google Scholar
• MiddletonJPWolfMSecond chances to improve ESRD outcomes with a second-generation calcimimeticJAMA2017317213914128097342
   PubMed Web of Science ®Google Scholar
• HaradaKETELCALCETIDE(ONO-5163, AMG 416), an intravenously available allosteric modulator of the calcium sensing receptor, effectively controls parathyroid hormone levels in a rat chronic renal insufficiency model with secondary hyperparathyroidismNephrol Dial Transplant201631Suppl 1i246i258
   Google Scholar
• StollenwerkBIannazzoSAkehurstRAssessing the cost-utility of Etelcalcetide: a Markov modelAbstract presented at: ISPOR 19th Annual European CongressOctober 31, 2016Vienna, Austria
   Google Scholar
• StollenwerkBIannazzoSCooperKBelozeroffVExploring the potential value of improved care for secondary hyperparathyroidism (SHPT) with a novel investigational calcimimetics therapyAbstract presented at: ISPOR 19th Annual European CongressOctober 31, 2016Vienna, Austria
   Google Scholar
• GinchermanYMoloneyKMcKeeCCoyneDWAssessment of adherence to cinacalcet by prescription refill rates in hemodialysis patientsHemodial Int201014687219732171
   PubMed Web of Science ®Google Scholar